| Project/Area Number |
17K16778
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
Okato Atsushi 千葉大学, 医学部附属病院, 医員 (90756719)
|
|---|
| Project Period (FY) |
2017-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | マイクロRNA / 治療抵抗性腎癌 / 腎細胞癌 |
|---|
| Outline of Final Research Achievements |
In recent years, although the development of new therapeutic agents for the advanced renal cell carcinoma have progressed, its effects are limited, and it is considered that elucidation of molecular pathways for acquiring treatment resistance is indispensable.
We generated a "treatment resistant renal cell carcinoma microRNA expression profile" from autopsy specimens after molecular targeted therapeutic agent treatment and identified microRNAs whose expressions are altered in cancerous tissue. As a result of searching for molecular networks controlled by these microRNAs, genes involved in cancer metastasis were identified. Genes targeted by these microRNAs have been confirmed to be a prognostic factor in renal cell carcinoma from the database of TCGA (the cancer genome atlas).
|
| Academic Significance and Societal Importance of the Research Achievements |
近年開発された分子標的治療薬は、進行腎細胞癌に対しても一定の治療効果を上げているが、治療経過中に抵抗性を獲得することが多く、その分子経路は十分に解明されていない。我々は分子標的治療薬治療後の剖検検体から、「治療抵抗性腎細胞癌マイクロRNA発現プロファイル」を作成し、癌組織で発現が抑制されているマイクロRNAの探索を行った。これらマイクロRNAが制御する分子ネットワークを探索した結果、癌の転移に関与する遺伝子を同定した。これらの遺伝子を標的とした治療薬の開発することは、新たな治療薬の開発の一助となると思われる。
|
